The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Be able to provide informed consent.
Be 18 years or older at the time of informed consent.
Histologically confirmed ACC, any site of origin.
Have locally advanced or metastatic ACC
Known hypersensitivity or contraindication to any component of REM-422 or to drugs chemically related to REM-422 or its excipients.
Clinically significant active infection. Simple urinary tract infection, uncomplicated bacterial pharyngitis responding to active treatment are permitted. Participants receiving intravenous antibiotics ≤ 7 days prior to enrollment are excluded (prophylactic antibiotics, antivirals or antifungals are permitted).
Evidence of active HIV infection.
Evidence of currently active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Remix Therapeutics
Lead sponsor